federal_register: 2012-27146
This data as json
| document_number | title | type | abstract | publication_date | pub_year | pub_month | html_url | pdf_url | agency_names | agency_ids | excerpts |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2012-27146 | Public Workshop on Burkholderia: Exploring Current Issues and Identifying Regulatory Science Gaps | Notice | The Food and Drug Administration (FDA) is announcing the following meeting: "Public Workshop on Burkholderia: Exploring Current Issues and Identifying Regulatory Science Gaps." An interagency planning committee led by FDA, in collaboration with the Defense Threat Reduction Agency; the National Institute of Allergy and Infectious Diseases, a component of the National Institutes of Health; the Centers for Disease Control and Prevention; the U.S. Army Medical Research Institute of Infectious Diseases; the Biomedical Advanced Research and Development Authority; the Chemical Biological Medical Systems Joint Project Management Office; the U.S. Strategic Command Center for Combating Weapons of Mass Destruction; and the Joint Science and Technology Office for Chemical and Biological Defense, developed this workshop to present the most current information on melioidosis (caused by Burkholderia pseudomallei) and glanders (caused by B. mallei), with the general purpose of building on information presented at previous meetings and identifying future areas of research needed to advance animal model development and to advance candidate medical countermeasures (MCMs) for approval, licensure, or clearance. | 2012-11-07 | 2012 | 11 | https://www.federalregister.gov/documents/2012/11/07/2012-27146/public-workshop-on-burkholderia-exploring-current-issues-and-identifying-regulatory-science-gaps | https://www.govinfo.gov/content/pkg/FR-2012-11-07/pdf/2012-27146.pdf | Health and Human Services Department; Food and Drug Administration | 221,199 | The Food and Drug Administration (FDA) is announcing the following meeting: "Public Workshop on Burkholderia: Exploring Current Issues and Identifying Regulatory Science Gaps." An interagency planning committee led by FDA, in collaboration with the... |